Home › Compare › SRWRF vs ABBV
SRWRF yields 10000.00% · ABBV yields 3.06%● Live data
📍 SRWRF pulled ahead of the other in Year 1
Combined, SRWRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SRWRF + ABBV for your $10,000?
SolarWorld Aktiengesellschaft manufactures and sells solar power products for on-grid and off-grid applications worldwide. The company operates through Production Germany, Production U.S., and Trade segments. It offers Sunmodule Plus, Sunmodule Bisun, and Sunmodule XL solar modules. The company also provides SolarWorld Kits, which comprises components required for constructing and operating a solar power system; Sundeck, a roof-integrated solution suitable for rooftop covers and refurbishment projects; Sunfix Plus, a mounting system for pitched or flat roofs; and Sunfix aero and Sunfix Bisun flat roof mounting systems. In addition, it offers Suntrol for system data monitoring; Suntool, a planning software for architects, fitters, planners, and wholesale traders; Sunplug eco, an inverter for domestic solar systems; KOSTAL inverters; and Sunpass, which provides planning, installation, and documentation of key data of solar array. Further, the company distributes solar systems and modules, as well as sells wafers and cells. It offers solar energy solutions to home and business owners, and energy suppliers. SolarWorld Aktiengesellschaft was founded in 1988 and is headquartered in Bonn, Germany.
Full SRWRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.